2Magliani W, Conti S, Ciociola T, et al. Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomod- ulatory auto-delivering drugs [ J ]. Future Med Chem,2011, 3(9) :1 209- 1 231. 被引量：1
3Eckert R. Road to clinical egicacy: challenges and novel strategies for antimicrobial peptide development [ J ]. Future Microbio1,2011,6 (6) :635 - 651. 被引量：1
4Weinrauch Y, Abad C, Liang NS, et al. Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2 [ J ]. J Clin Invest, 1998,102 (3) :633 - 638. 被引量：1
5Brouwer CP, Rahman M, Welling MM. Discovery and devel- opment of a synthetic peptide derived from lactoferrin for clinical use[J]. Peptides,2011,32(9) :1 953 -1 963. 被引量：1
6Weiss J,Inada M,Elsbach P,at al. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes[ J]. J Biol Chem,1994,269(42) :26 331 -26 337. 被引量：1
8Hein-Kristensen L, Knapp KM, Franzyk H, et al. Bacterial membrane activity of α-peptide/β-peptoid chimeras :influence of amino acid composition and chain length on the activity against different bacterial strains [ J ]. BMC Mierobiol,2011, 11:144 - 156. 被引量：1
9Koprivnjak T, Peschel A, Gelb MH, et al. Role of charge properties of bacterial envelope in bactericidal action of human group IIA phospholipase A2 against Staphylococcus aureus[ J]. J Biol Chem,2002,277(49) :47 636 -47 644. 被引量：1
